In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will get treatment until condition progression or even the individuals are not able to tolerate the study drugs. Ubiquitin-connected proteins that regulate The steadiness of vital Tremendous enhancer-mediated proteins have https://abbv-744-brd4-inhibitor-c25791.theblogfairy.com/31404282/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know